本文由定制化的企业情报智能服务平台——【情报强企】提供
标签：#cell therapy
Therapeutic Solutions International，股份有限公司（TSOI）今天宣布开发一种新的治疗额颞叶痴呆的方法，通过将神经系统中内源性抗炎细胞的激活与干细胞疗法形式的再生细胞干预相结合，以及能够激活已经存在于患者体内的内源性干细胞的分子。
Therapeutic Solutions International, Inc. (TSOI), announced today the development of a new therapeutic approach for treatment of Frontotemporal Dementia, by combining the activation of endogenous anti-inflammatory cells in the nervous system, together with regenerative cell intervention in the form of stem cell therapy, and molecules capable of activating endogenous stem cells already present in the patient.
该疗法已提交专利申请，并在该疾病的动物模型中证明了积极的初步数据。该公司计划根据“审判权法”，通过Veltmeyer研究所为患有这种疾病的“无选择”患者提供治疗。
The therapy, for which a patent application has been filed, has demonstrated positive preliminary data in an animal model of the condition. The Company plans to make the therapy available to "no option" patients with this condition through the Veltmeyer Institute under the "Right to Try Law".
该公司首席医疗官James Veltmeyer博士说：“额颞叶痴呆是一种多种不同的疾病，我们已经根据患者的遗传、细胞和生化特征制定了一个特定的诊断标准。”。“使用这些基准，我们提供了一种个性化的鸡尾酒，包括JadiCell异基因脐带间充质干细胞、美国食品药品监督管理局批准的激活神经干细胞的化合物、美国食品和药物管理局批准了的免疫调节剂，以及适当的经颅磁刺激。”
"Frontotemporal dementia is a myriad of different conditions that we have developed a specific diagnostic criterion based on genetic, cellular, and biochemical characteristics of the patients," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "Using these benchmarks, we provide a personalized cocktail comprised of JadiCell allogeneic umbilical cord mesenchymal stem cells, FDA cleared compounds that activate neurological stem cells, FDA cleared immune modulators, and where appropriate transcranial magnetic stimulation."
坎贝尔神经科学公司总裁兼首席执行官Thomas Ichim博士表示：“免疫系统和神经系统是身体中仅有的两个具有记忆、特异性和区分自我与非自我能力的系统。”坎贝尔神经科学是国际治疗解决方案公司的子公司，也是该公司的董事会成员。“我很高兴参与由Veltmeyer博士和合作者领导的这项发现，他们利用坎贝尔正在进行的将免疫系统用作健康和病理心理过程听诊器的工作。”
"The immune system and the nervous system are the only two systems of the body which have memory, specificity, and the ability to distinguish self from non-self," stated Dr. Thomas Ichim, President, and CEO of Campbell Neurosciences, a subsidiary of Therapeutic Solutions International and Board Member of the Company. "I am enthusiastic to have participated in the discovery led by Dr. Veltmeyer and collaborators which leveraged ongoing work at Campbell related to using the immune system as a stethoscope for healthy and pathological mental processes."
Therapeutic Solutions International是一家孵化器和“治疗加速器”，该公司总裁兼首席执行官Timothy G.Dixon表示。“额颞叶痴呆症是一种可怕的疾病，没有可以改变疾病的治疗方法。我们相信，通过跳出框框进行搜索，事实上是在与框框完全不同的维度上进行搜索，我们增加了这种疾病的技术水平，我们希望这将加速进展并最终治愈。”
Therapeutic Solutions International is an incubator and "therapeutic accelerator," said Timothy G. Dixon, President, and Chief Executive Officer of the Company. "Frontotemporal Dementia is a terrifying condition with no disease modifying treatments available. We believe that by having searched outside of the box, in fact on a totally different dimension from the box, we have added to the state of the art in this condition, which we hope will accelerate progress and eventual cure"
本文内容来源于网络资料，由【情报强企】整理